SCHEMBL2567306

SCHEMBL2567306

COc1cc(Cl)c(OBOc2cc(OC)c(OC)cc2Cl)cc1OC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.48
NPC1 O15118 2/20 0.43
TAAR1 Q96RJ0 1/20 0.41
ALDH1A1 P00352 5/20 0.39
MAPT P10636 4/20 0.39
MAPK1 P28482 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
RAB9A P51151 2/20 0.39
HSP90AA1 P07900 1/20 0.39
PKM P14618 1/20 0.39
CCR6 P51684 1/20 0.39
CACNA1B Q00975 1/20 0.39
APBA1 Q02410 1/20 0.39
APOBEC3G Q9HC16 1/20 0.39
ACHE P22303 1/20 0.38
HPGD P15428 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
MEN1 O00255 1/20 0.38
USP2 O75604 1/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5633315 0.85 GAA (0.39) GAANPC1TAAR1ALDH1A1MAPT
SCHEMBL27952777 0.83 GAA (0.65) GAANPC1TAAR1ALDH1A1MAPT
SCHEMBL30487990 0.83 GAA (0.65) GAANPC1TAAR1ALDH1A1MAPT
SCHEMBL5572861 0.77 GAA (0.50) GAANPC1TAAR1ALDH1A1MAPT
Chloroneb SCHEMBL22739 0.77 GAA (0.64) GAANPC1TAAR1ALDH1A1MAPT
SCHEMBL16609990 0.75 GAA (0.68) GAANPC1TAAR1ALDH1A1MAPT
SCHEMBL3480776 0.74 TAAR1 (0.39) GAATAAR1ALDH1A1MAPTACHE
SCHEMBL3537469 0.74 TRPV4 (0.47) ALDH1A1MAPK1ACHEMEN1KMT2A
SCHEMBL262721 0.72 CA12 (0.48) GAAALDH1A1MAPTHSP90AA1L3MBTL1
SCHEMBL177471 0.72 CA12 (0.43) GAANPC1ALDH1A1MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2007767-B1 PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS VERNALIS R&D LTD (GB) 2011-11-02 EP disclosed
US-20090163490-A1 Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors VERNALIS (R&D) LTD. (GB) 2009-06-25 US disclosed
EP-2007767-A1 PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS VERNALIS (R&D) LTD (GB) 2008-12-31 EP disclosed
WO-2007104944-A1 PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS VERNALIS (R & D) LTD. (GB) 2007-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163490-A1 Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors HSP90AA1, HSP90AB1, RAF1 GAA 4273/4885NPC1 3832/4885TAAR1 2932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.